menu
    • menu
    [{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LAXAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LAXAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LAXAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"CSIR-Indian Institute of Chemical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LAXAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LAXAI Life Sciences \/ CSIR-Indian Institute of Chemical Technology","highestDevelopmentStatusID":"8","companyTruncated":"LAXAI Life Sciences \/ CSIR-Indian Institute of Chemical Technology"}]

    Find Clinical Drug Pipeline Developments & Deals by LAXAI Life Sciences

    Menu

    LAXAI Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LAXAI Life Sciences

                            India arrow
                            Cophex
                            Not Confirmed

                            LAXAI Life Sciences

                            India arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niclosamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : CSIR-Indian Institute of Chemical Technology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Clinical Trial of Niclosamide Drug for Treatment of Covid-19 Patients Begins

                            Details : The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 06, 2021

                            Lead Product(s) : Niclosamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : CSIR-Indian Institute of Chemical Technology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LAXAI Life Sciences

                            India arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            LAXAI Life Sciences

                            India arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Favipiravir,Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CSIR Seeks Regulatory Nod for Clinical Trials Using Combination of Antivirals and HDTs Against COVID-19

                            Details : Study will combine and repurpose antivirals and host-directed therapies and to determine safety & efficacy of a combination of drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 07, 2020

                            Lead Product(s) : Favipiravir,Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth